Keensight Buys Majority Stake in Isto in $1 Billion Deal
PositiveFinancial Markets

Keensight Capital has made a significant move by acquiring a majority stake in Isto Biologics for $1 billion, marking a notable trend in mid-sized deals within the private equity sector. This acquisition not only strengthens Keensight's portfolio but also highlights the growing interest in the orthobiologic market, which is crucial for advancing medical treatments.
— Curated by the World Pulse Now AI Editorial System